Home > Healthcare > Medical Devices > Implantable Devices > Sleep Apnea Implants Market
Sleep Apnea Implants Market size exceeded USD 311 million in 2021 and is estimated to register around 16% CAGR through 2030. The rising incidence of sleep apnea disorder is the key factor propelling the global market growth.
The economic burden of sleep apnea disorder & undiagnosed cases inflicts significant toll on the healthcare ecosystem. For instance, according to a published report in 2021, the socio-economic burden of obstructive sleep apnea inflicts both direct and indirect health-related costs accounting for around USD 67 to USD 165 billion annually in the U.S. Thus, the heightened healthcare costs along with the surging adoption of sleep apnea implants are predicted to fuel the sleep apnea implants industry outlook.
Report Attribute | Details |
---|---|
Base Year: | 2021 |
Sleep Apnea Implants Market Size in 2021: | USD 311.1 million |
Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 16.3% |
2030 Value Projection: | USD 1,294.0 million |
Historical Data for: | 2017 to 2021 |
No. of Pages: | 100 |
Tables, Charts & Figures: | 164 |
Segments covered: | Product, Indication, End-use, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Sleep apnea implants refers to discreet devices implanted in the patient’s body to stimulate the natural breathing mechanism, open the airway, and enable the oxygen flow. Sleep apnea implants aid in reducing the impact of sleep apnea & the devices are majorly used in managing moderate to severe sleep apnea.
However, high costs associated with sleep apnea implants, stringent government regulations, and peri-operative complications may negatively impact the business growth. The high cost of sleep apnea implants, specifically the hypoglossal neurostimulation devices & phrenic nerve stimulator may affect the adoption rate of these devices, thereby affecting the market growth.
For instance, as of 2019, the Inspire Medical System’s hypoglossal nerve stimulation implant was priced at USD 23,800 in the U.S. & USD 23,400 in Europe. Such incremental costs would affect the adoption of these sleep apnea implants. Furthermore, the U.S. FDA overviews the R&D activities, approval, and post-approval surveillance associated with medical devices, including sleep apnea implants. Certain sleep apnea implants, including the Inspire UAS system is classified as class III medical device. These devices are required to adhere to stringent regulatory approval processes & compliances including the premarket approval (PMA). Thus, the strict regulatory framework & high cost may limit the adoption of sleep apnea implants, further hindering the industry growth.
The COVID-19 pandemic arose as an unparalleled health pandemic and impacted the industrial sectors by hampering the supply chain. The pandemic slowed down the sleep apnea implants market growth, during the initial phase of the pandemic, in the first half of 2020. To contain the spread of the SARS-CoV-2 virus, national emergencies and lockdowns were enforced in several economies.
The shutdown and movement restrictions impacted the medical practices. The coronavirus pandemic affected the medical device industry by limiting the product adoption & associated procedures. It affected the business operations of market players by substantially decreasing and delaying the number of implantation procedures performed and patients screened for the eligibility of sleep apnea implants therapy.
Additionally, the industry players also faced certain challenges in recruiting patients for clinical trials owing to the pandemic. However, the collaborative efforts of certain regulatory agencies and market players aided in mitigating the impact of pandemic.
or instance, as per the Inspire Medical Systems, all Inspire therapy procedures scheduled in March 2020 were either cancelled or postponed. Although by October 2020, majority of the surgical centers were performing these implantation procedures. Further in 2021, elective surgical procedures achieved the pre-pandemic surgical volume. Thus, the COVID-19 pandemic had slightly slowed down the industry growth; although, the restoring surgical volume would facilitate the market growth in near future.
Substantial surge in the number of patients affected with sleep apnea is amongst the major factors propelling the demand for sleep apnea implants. Obstructive sleep apnea (OSA) is a chronic ailment that is notably underdiagnosed and results in frequent breathing interruptions during sleep.
This condition occurs as the throat and tongue muscles along with soft tissues relax & collapse, thereby limiting the amount of air that reaches the lungs. OSA promotes significant health consequences and co-morbidities, including cardiovascular conditions, atherosclerosis, heart failure, hypertension, stroke, diabetes, and depression among others that also results in substantial mortality.
As per the Lancet Respiratory Medicine journal, published in 2019, OSA is the most profound sleep disorder, affecting approximately 936 million people globally. Around 425 million individuals suffer with moderate-to-severe OSA that require treatment. Similarly, in Germany, around 14.3 million people suffer from this condition as of 2019.
As a result, with the surging patient population, the market is anticipated to foresee significant growth pertaining to the rising adoption & awareness regarding sleep apnea implants. Thus, as these implants offer an effective solution to patients for managing obstructive sleep apnea, the market is projected to witness unprecedented growth in the foreseeable future.